Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Eli Lilly (NYSE:LLY) has invested in Abridge, an AI-focused clinician documentation company. The partnership connects Lilly to Abridge's clinical conversation data platform, used across hundreds of health systems. The deal is aimed at using AI tools to speed up drug development, clinical trial enrollment, and evidence-based research. Eli Lilly is widely followed for its pharmaceutical portfolio, including obesity treatments and other therapies that have driven much of the recent discussion...
Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks stood out.
With the massive SpaceX debut hogging the headlines, some retail investors may have allowed more prosaic names to slip from their minds. Pharma stock Eli Lilly is trading in a buy zone as institutional investors load up. Eli Lilly is committed to innovation and reinvests 20%-25% of its sales back into developing new treatments.
The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.
Eli Lilly and Company (NYSE:LLY) is one of the 7 Best Compounder Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) plans to stop providing 340B discounted drug pricing to certain hospitals that have not complied with claims data reporting requirements introduced on February 1, Fierce Healthcare’s Dave Muoio reported. The move has drawn opposition […]
Eli Lilly (NYSE:LLY) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the back of the GLP-1 mania. But here’s what you should actually be watching. The Hot Ticker Is a Two-Drug Bet at a Trillion-Dollar Price Strip away the ... Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy
Eli Lilly and Company (NYSE:LLY) rose around 12% in May 2026, primarily driven by strong FQ1 2026 earnings beat and FDA approval for Foundayo and expansion of insurance coverage of obesity treatment. With 132 hedge funds holding the stock as of Q1 2026, Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to […]
(Updates with Eli Lilly's response to a request for comment from MT Newswires.) Some employers in
There are already lengthy patient waitlists for the medication on digital health platforms.
The company is working with Nvidia to build a foundation model for clinical conversations, and it scored a strategic investment from drugmaker Eli Lilly, Abridge announced during a sweeping keynote Thursday.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy, according to analysts. On June 7, Eli Lilly and Company (NYSE:LLY) announced top-line results for Foundayo (orforglipron), the only oral GLP-1 that can be taken without food or water restrictions. Clinical trial results showed that women with obesity and who were […]
Investing.com -- Elon Musk’s SpaceX on Thursday said that it has priced its initial public offering at $135 per share on Thursday, raising $75 billion in the largest IPO in U.S. history.
Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the GLP-1 duopoly apart. Lilly grew revenue 55.5% and raised guidance. Novo posted a 4% adjusted sales decline at constant currency and is cutting 9,000 jobs. Both call obesity the prize, but their quarters tell very different stories about who ... Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy
The $5.3 billion ambient AI startup is expanding from clinical notes into billing, drug trials, and real-time insurance claims.
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
Rising use of weight-loss drugs keeps pressure on health benefit costs.
ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.
The AI boom has been built on a simple assumption: the companies with the best models will capture most of the value. That belief helped push valuations for leading AI developers into the hundreds of billions of dollars and turned model performance benchmarks into headline news. But markets have a habit of changing the rules. ... An AI Price War Is About to Break Out. You Won’t Believe Who Will Profit Most
Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the drugs are reducing fast food’s addressable market by an estimated 27-30%. This is structural, not cyclical: appetite, ... The GLP-1 stock nobody is pricing in isn’t a drugmaker
FDA approves an extended once-every-eight-weeks maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis. The decision expands Eli Lilly's (NYSE:LLY) dermatology footprint beyond its obesity and diabetes drug franchises. Ebglyss already has broad coverage from national pharmacy benefit managers, and the new regimen provides added dosing flexibility for patients. For you as an investor, this FDA decision adds another dimension to Eli Lilly's...
I keep buying NVIDIA, Eli Lilly, and Johnson & Johnson, and if a fire took my brokerage statement to zero tomorrow, those are the three tickers I would start typing in again on day one. They each do something I cannot replicate by being clever. Why the buy button stays active on NVIDIA NVIDIA (NASDAQ:NVDA) ... I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
LLY wins FDA approval for every-8-week Ebglyss maintenance dosing in eczema, reducing injections per year while maintaining long-term disease control.
